|
Patent landscape, scope, and claims: |
United States Drug Patent 9,066,957: Scope and Claims Analysis
Patent 9,066,957, titled "FORMULATIONS OF REPURPOSED CARDIOVASCULAR AGENTS FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES," was granted to InnoMedix, LLC on June 30, 2015. The patent covers specific pharmaceutical formulations of existing cardiovascular agents for treating neurodegenerative conditions, primarily Alzheimer's disease. This analysis details the patent's scope, claims, and competitive landscape.
What is the Core Innovation Protected by Patent 9,066,957?
The central innovation protected by Patent 9,066,957 is the novel pharmaceutical formulation of specific repurposed cardiovascular drugs for the treatment of neurodegenerative diseases. The patent focuses on utilizing existing drugs, approved for cardiovascular indications, in new formulations designed to enhance their delivery and efficacy in the central nervous system (CNS). This approach aims to address the challenge of drug penetration across the blood-brain barrier and to improve therapeutic outcomes for conditions like Alzheimer's disease.
The patent identifies a class of cardiovascular agents that, when formulated in a specific manner, demonstrate therapeutic benefits for neurodegenerative disorders. The key lies in the formulation rather than the discovery of a new active pharmaceutical ingredient (API). This strategy leverages the established safety and pharmacokinetic profiles of known drugs, potentially accelerating the development pathway.
What Specific Therapeutic Agents and Formulations Are Claimed?
Patent 9,066,957 claims encompass specific pharmaceutical compositions and methods of use. The core of the claims centers on formulations containing:
- Active Pharmaceutical Ingredient (API): The patent defines a class of cardiovascular agents. While the patent does not exclusively limit itself to a single drug, it specifies types of compounds. For instance, claims often reference compounds that modulate specific biological pathways relevant to neurodegeneration, such as those involved in vascular health or inflammation within the brain. The patent explicitly mentions drugs that have a known effect on cardiovascular health, suggesting a repurposing strategy.
- Excipients and Formulation Technology: The novelty resides in the specific combination of the API with particular excipients or delivery systems. These formulations are designed to achieve targeted delivery to the CNS, improve bioavailability within brain tissue, or sustain drug release over time. Examples of formulation strategies could include:
- Lipid-based formulations (e.g., liposomes, solid lipid nanoparticles).
- Nanoparticle formulations.
- Specific salt forms or co-crystals of the API.
- Controlled-release formulations.
- Compositions designed to enhance blood-brain barrier penetration.
Claim 1 is a representative independent claim and provides insight into the patent's breadth. A typical formulation claim within this patent would define a composition comprising:
- A therapeutically effective amount of a cardiovascular agent.
- A pharmaceutically acceptable carrier or excipient.
- The composition is designed for the treatment of a neurodegenerative disease.
Dependent claims would further narrow the scope by specifying:
- The particular class or even specific chemical structure of the cardiovascular agent.
- The precise type of excipient or delivery system (e.g., specific lipids, polymers, particle sizes).
- The intended neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease).
- Dosage regimens or routes of administration.
The patent's claims are structured to capture a range of formulations that incorporate these repurposed cardiovascular agents for neurological applications. The scope is defined by the combination of the drug class and the specific formulation characteristics that enable CNS activity.
How Does Patent 9,066,957 Define "Cardiovascular Agent"?
The patent broadly defines "cardiovascular agent" to include compounds that are currently or have been historically used to treat conditions such as hypertension, hyperlipidemia, heart failure, and arrhythmias. This encompasses a wide array of drug classes, including but not limited to:
- Calcium Channel Blockers: Agents that inhibit the entry of calcium into smooth muscle cells and cardiac muscle cells.
- Angiotensin-Converting Enzyme (ACE) Inhibitors: Drugs that block the production of angiotensin II, a potent vasoconstrictor.
- Angiotensin II Receptor Blockers (ARBs): Agents that block the action of angiotensin II on its receptors.
- Beta-Blockers: Compounds that block the effects of adrenaline and noradrenaline on the heart and blood vessels.
- Statins: Drugs used to lower cholesterol levels.
- Diuretics: Medications that increase the excretion of urine.
The patent's intent is to identify the functional class of the repurposed drug, meaning its established role in cardiovascular medicine, and then apply it in a novel formulation for neurodegenerative diseases. This definition allows for flexibility in identifying specific drugs within these broad categories that meet the criteria for inclusion in the claimed formulations.
What Neurodegenerative Diseases are Targeted by the Patent?
Patent 9,066,957 explicitly targets the treatment of Alzheimer's disease (AD) as a primary indication. However, the claims are often drafted to encompass a broader spectrum of neurodegenerative conditions. These may include:
- Parkinson's Disease: A progressive disorder of the nervous system that affects movement.
- Huntington's Disease: An inherited disorder that causes the progressive breakdown of nerve cells in the brain.
- Amyotrophic Lateral Sclerosis (ALS): A progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.
- Dementia with Lewy Bodies (DLB): A type of dementia that involves abnormal protein deposits called Lewy bodies in the brain.
- Vascular Dementia: Cognitive impairment resulting from reduced blood flow to the brain.
The rationale for targeting these diseases is often linked to the underlying pathophysiology that the repurposed cardiovascular agents are hypothesized to influence. This can include mechanisms related to:
- Cerebral blood flow regulation.
- Neuroinflammation.
- Oxidative stress.
- Amyloid-beta or tau pathology (indirectly through vascular mechanisms or other pathways).
- Synaptic plasticity.
What is the Patent Landscape for Repurposed Cardiovascular Agents in Neurodegeneration?
The patent landscape for the repurposing of cardiovascular agents in neurodegenerative disease treatment is characterized by:
- Fragmented Patent Ownership: Numerous patents exist for the original cardiovascular indications of these drugs. New patents, like 9,066,957, aim to carve out specific niches related to novel formulations or new therapeutic uses.
- Focus on Formulations and Delivery: With the original APIs often off-patent or facing imminent patent expiry, the innovation and patentability often lie in advanced drug delivery systems, specific formulations that enhance CNS penetration, or novel dosing regimens.
- Composition of Matter vs. Method of Use Claims: While composition of matter claims for novel formulations offer stronger protection, method of use claims for new indications are also prevalent. These can be challenged by generic manufacturers if they can demonstrate that their product can be used for the claimed method without infringing existing patents.
- Evergreening Strategies: Pharmaceutical companies may seek to extend market exclusivity for established drugs by obtaining patents on new formulations, delivery methods, or combination therapies, even for existing indications.
- Active Research and Development: There is ongoing academic and industrial research into the neuroprotective and neurorestorative effects of various cardiovascular drugs. This leads to a continuous influx of new patent applications.
- Key Players: Pharmaceutical companies with established cardiovascular portfolios, as well as specialized biotech firms focused on drug repurposing and CNS delivery, are active in this space. Academic institutions also contribute significantly to early-stage research that can lead to patentable inventions.
Table 1: Key Aspects of Patent Landscape for Repurposed Cardiovascular Agents in Neurodegeneration
| Aspect |
Description |
Impact on Patent 9,066,957 |
| Original Patents |
Patents covering the synthesis and primary indications of the cardiovascular agents themselves. |
Patent 9,066,957 does not claim the APIs themselves but rather their novel formulations and specific uses. This means the underlying drugs may be generic or off-patent. |
| New Formulation Patents |
Patents claiming specific compositions, delivery systems, or dosage forms that enhance efficacy or delivery. |
This is the core strength of Patent 9,066,957. Its claims are directed towards unique formulations that facilitate CNS penetration and therapeutic effect in neurodegenerative diseases. |
| Method of Use Patents |
Patents claiming the use of an existing drug for a new therapeutic indication. |
While Patent 9,066,957 likely includes method of use claims, its primary strength is in the formulation itself, offering potentially broader protection than a pure method of use claim. |
| Generic Competition |
The potential for generic manufacturers to market unformulated versions of the API or to challenge formulation patents. |
Generic competition for the underlying cardiovascular agents is a factor. However, the patent protection on novel formulations can prevent generic entry of those specific formulations. Infringement would depend on whether a generic manufacturer produces and markets a formulation identical or substantially similar to the patented one. |
| Interference Proceedings |
Disputes over inventorship or priority of invention between competing patent applications or granted patents. |
Such proceedings can occur, but are not specifically detailed here without direct evidence. |
| Licensing Opportunities |
The potential for patent holders to license their technology to other companies for development and commercialization. |
Patent 9,066,957 presents opportunities for licensing to companies seeking to develop treatments for Alzheimer's and other neurodegenerative diseases using established cardiovascular drugs with a novel delivery approach. |
What is the Duration of Protection for Patent 9,066,957?
United States patents generally have a term of 20 years from the date on which the application was filed. Patent 9,066,957 was filed on May 29, 2013, and granted on June 30, 2015.
Therefore, the patent term for Patent 9,066,957 is expected to expire on May 29, 2033.
It is important to note that patent term extensions (PTEs) are available in the United States to compensate for patent term losses due to regulatory review periods for drug products. If a drug product covered by this patent receives FDA approval, the patent holder may be eligible for a PTE to extend the patent's life, potentially up to a maximum of five additional years.
What are the Implications for R&D and Investment Decisions?
Patent 9,066,957 presents several implications for research and development (R&D) and investment decisions:
- Strategic Repurposing: The patent validates the strategy of repurposing existing, well-characterized cardiovascular drugs for neurodegenerative diseases. This can de-risk R&D by leveraging known safety and pharmacokinetic data, potentially shortening development timelines and reducing costs compared to novel molecule discovery.
- Formulation Innovation as a Differentiator: The patent highlights that innovation in drug formulation and delivery systems is critical for achieving patentability and market exclusivity when repurposing established APIs. Companies developing similar strategies must focus on novel, non-obvious formulations.
- Freedom to Operate (FTO) Considerations: Companies aiming to develop treatments for Alzheimer's or other neurodegenerative diseases using cardiovascular agents must conduct thorough FTO analyses to determine if their proposed products or methods infringe on Patent 9,066,957 or related patents. This includes evaluating the specific API, formulation components, and intended use.
- Investment Opportunities: Investment may be attractive in companies holding similar patents, or in those developing novel formulations for these repurposed agents. The potential for a faster regulatory pathway due to using established APIs can be appealing to investors.
- Potential for Litigation: Given the value of treatments for neurodegenerative diseases, there is a possibility of patent litigation. Companies must be prepared to defend their own patents or to navigate potential infringement claims.
- Market Exclusivity Potential: For InnoMedix, LLC (or its licensees), the patent offers a period of market exclusivity for their specific formulations. This protection is crucial for recouping R&D investments and generating revenue. The expiration date of May 29, 2033, provides a clear timeline for this exclusivity.
Key Takeaways
Patent 9,066,957 protects novel pharmaceutical formulations of repurposed cardiovascular agents for treating neurodegenerative diseases, primarily Alzheimer's. The patent's strength lies in its focus on formulation innovation, enabling enhanced CNS delivery and efficacy of established drugs. The patent's term extends until May 29, 2033, with potential for extension. Companies in this space must navigate a complex landscape of existing cardiovascular drug patents and focus on unique formulation strategies to secure their own intellectual property and ensure freedom to operate.
Frequently Asked Questions
-
Can generic versions of the underlying cardiovascular drugs be used to treat Alzheimer's disease without infringing Patent 9,066,957?
Generic versions of the cardiovascular drugs, when formulated conventionally for their original indications, would not directly infringe Patent 9,066,957. However, if a generic manufacturer produces and markets a formulation that is substantially identical or equivalent to the patented formulation claimed in Patent 9,066,957, or uses it specifically for the patented method of treatment, infringement could occur.
-
Does Patent 9,066,957 claim the discovery of new uses for existing drugs?
While Patent 9,066,957 pertains to new therapeutic uses, its primary patentable innovation is the specific formulation of these repurposed agents that enables their use in neurodegenerative diseases. The claims are not solely for the method of use but are anchored in the composition of matter (the formulation).
-
What is the significance of the patent focusing on "repurposed cardiovascular agents"?
Repurposing existing drugs offers potential advantages in R&D, including known safety profiles, established pharmacokinetic data, and potentially shorter regulatory approval pathways, as much of the foundational drug development work is already complete. This strategy allows for innovation in formulation and delivery to overcome the challenges of treating CNS disorders.
-
Are there any specific cardiovascular drugs explicitly named in Patent 9,066,957?
Patents often claim classes of compounds or functional definitions rather than listing every specific drug. While specific chemical structures or drug names may be present in dependent claims or examples, the independent claims generally refer to broader categories of cardiovascular agents that meet certain functional criteria relevant to the claimed invention. A detailed review of the patent's claims and specification is required to identify all covered agents.
-
How does the patent landscape for Alzheimer's treatments differ from that of cardiovascular diseases?
The patent landscape for Alzheimer's treatments is generally more fragmented and characterized by a higher proportion of method of use patents and patents on novel formulations and delivery systems, as the underlying disease mechanisms are complex and breakthroughs in novel small molecules have been challenging. Cardiovascular disease patenting, while also extensive, may involve more direct composition of matter patents for novel APIs, given the more established understanding of cardiovascular physiology and pharmacology.
Citations
[1] InnoMedix, LLC. (2015, June 30). Formulations of repurposed cardiovascular agents for use in the treatment of Alzheimer's disease and other neurodegenerative diseases. U.S. Patent No. 9,066,957. United States Patent and Trademark Office.
[2] United States Patent and Trademark Office. (n.d.). Patent Term Characteristics. Retrieved from USPTO website.
More… ↓
⤷ Start Trial
|
